Common questions
PT-141: the recurring questions, answered straight.
Direct answers to the questions readers ask most about PT-141 (bremelanotide), with every quantitative claim cited to the published record.
What is PT-141?
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide that acts as a melanocortin (MC3R/MC4R) receptor agonist [1]. As bremelanotide it is FDA-approved (2019, NDA 210557) for HSDD in premenopausal women [6]. PT-141 and bremelanotide are the same molecule under two names.
What is PT-141 peptide?
A seven-amino-acid cyclic lactam analogue of alpha-MSH, sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, molecular weight 1,025.2 Da [1]. The closed ring makes it more stable than linear melanocortin peptides, which is part of why it advanced through development where earlier candidates did not.
What does the PT-141 peptide do?
It activates central melanocortin receptors (chiefly MC4R) in hypothalamic and limbic circuits tied to sexual desire and arousal, acting on the brain's motivation circuitry rather than on blood flow [1]. A controlled fMRI study showed it altered how the brain processed erotic stimuli [5].
What is PT-141 used for?
Bremelanotide is approved for acquired, generalized HSDD in premenopausal women [6]. Every other use — in men, for erectile dysfunction, in postmenopausal women, or for performance — is off-label and not supported by the approval [6]. The approved indication is the only established use.
Is PT-141 the same as bremelanotide?
Yes — PT-141 is the development and research code, and bremelanotide is the international nonproprietary name (INN) for the same molecule [1]. The approved finished drug product is bremelanotide injection [6]. Different names, one compound.
What is bremelanotide?
Bremelanotide is the INN for PT-141, the melanocortin (MC3R/MC4R) receptor agonist approved in June 2019 (NDA 210557) for HSDD in premenopausal women [6]. It acts centrally on brain circuits governing sexual desire rather than on vascular blood flow [1].
How does PT-141 work?
By stimulating MC4R (and MC3R) in hypothalamic circuits such as the medial preoptic area, it is thought to engage dopaminergic pathways governing sexual desire and arousal — a central mechanism distinct from blood-flow drugs [1]. An fMRI study supports that central account [5].
What receptors does PT-141 act on?
Chiefly the melanocortin 4 receptor (MC4R), with secondary MC3R agonism, both concentrated in central nervous system circuits [1]. Peripheral MC1R activation underlies the hyperpigmentation seen with repeated dosing [6]. The central MC3R/MC4R pair drives the desire effect.
Does PT-141 work through the brain or through blood flow?
Through the brain. Unlike blood-flow drugs that act on vascular smooth muscle, PT-141 works centrally on the neural circuitry of sexual motivation [1]; an fMRI study showed it altered task-based brain processing of erotic stimuli [5]. The effect is central, not vascular.
What is a melanocortin receptor agonist?
A molecule that activates the melanocortin receptor family (MC1R-MC5R), which respond to peptides such as alpha-MSH [1]. PT-141 targets the central MC3R/MC4R subtypes that sit in brain circuits governing sexual desire and appetite [1].
Does PT-141 increase testosterone?
No. A common misconception — PT-141 does not act via the HPG axis and does not directly raise testosterone; it works on central melanocortin receptors, and it is not a blood-flow drug either [1]. Its desire effect is a brain-circuit effect.
How is PT-141 different from PDE-5 inhibitors?
PDE-5 inhibitors act peripherally on vascular smooth muscle to improve erectile blood flow; PT-141 acts centrally on melanocortin circuits of sexual desire and arousal [1]. Different target, different mechanism — which is why combination development has been explored [8].
How big is the effect of bremelanotide on sexual desire?
In the integrated Phase 3 RECONNECT analysis the effect was statistically significant but clinically modest: FSFI-desire +0.35 and FSDS-DAO item-13 -0.33 versus placebo [3]. Independent re-analyses (Spielmans 2021, 2024) argue the benefit is small [9][15]. A real, reproducible, small effect.
Does PT-141 cause weight loss?
Not an approved use. Because MC4R also sits in appetite circuits, two Phase 1 trials in obese women found reduced body weight (-1.3 kg versus placebo over 16 days) and roughly 400 kcal/day lower intake — at high-frequency research dosing, not the approved 1.75 mg as-needed regimen [7].
What is the PT-141 dosage?
Reported as a finding only: the bremelanotide label specifies 1.75 mg subcutaneously, as needed, with no more than one dose per 24 hours and no more than 8 doses per month [6]. This is the approved-product label, not a protocol for any reader to follow.
How much PT-141 should I take?
This site recommends no dose for any individual. The literature and label report 1.75 mg subcutaneous as-needed for the approved HSDD indication [6]; the approved product is prescription-only and dosing decisions belong to a prescriber.
How much PT-141 to inject?
The reported label dose is 1.75 mg subcutaneous as-needed [6]; Phase 2 dose-finding studied 0.75, 1.25, and 1.75 mg [6]. These are study and label figures, not a recommendation, and the approved product is a prepared single-dose autoinjector.
What is the PT-141 dosage for women?
For the approved HSDD indication in premenopausal women, the label specifies 1.75 mg subcutaneous as-needed, taken at least 45 minutes before anticipated activity, capped at one dose per 24 hours and 8 per month [6]. Reported as a finding, not a protocol.
How do you reconstitute PT-141?
The approved product is a prepared single-dose autoinjector, not a reconstituted preparation [6]. Material sold as 'PT-141 research chemical' is for laboratory use only; this site does not provide reconstitution or self-administration instructions.
How do you take PT-141?
Per the label, bremelanotide is given subcutaneously (abdomen or thigh) as needed, at least 45 minutes before anticipated sexual activity [6]. Reported here as the approved administration route, not as guidance to self-administer.
How often can you take PT-141?
The label limit is no more than one dose per 24 hours and no more than 8 doses per month [6]. High-frequency dosing appears only in research protocols, such as the Phase 1 obesity studies, not the approved regimen [7].
Why is PT-141 being studied with a PDE-5 inhibitor?
Because the two act on different systems — PT-141 centrally on melanocortin circuits of desire, blood-flow drugs peripherally on erectile vasculature [1]. Combination development explores whether central plus vascular action helps where one alone does not. This is investigational, not approved [8].